Trial Profile

Efficiency and safety of Anlotinib in platinum resistant or refractory ovarian cancer: a prospective, single arm, single center, exploratory phase 2 clinical trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary)
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use

Most Recent Events

06 Nov 2023 Results assessing efficacy and safety of anlotinib in patients with platinum resistant/refractory ovarian cancer, published in the International Journal of Gynecological Cancer.
21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
08 Jun 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com